vaccine clinical trial intelligence

Early Clinical Development of a Live, Attenuated Combination Vaccine Against Shigella and ETEC Diarrhoea: Phase 1b Clinical Trial of ShigETEC Vaccine in Bangladeshi Adults and Three Paediatric Age Groups

Early Clinical Development of a Live, Attenuated Combination Vaccine Against Shigella and ETEC Diarrhoea: Phase 1b Clinical Trial of ShigETEC Vaccine in Bangladeshi Adults and Three Paediatric Age Groups is a PHASE1 clinical asset sponsored by Eveliqure Biotechnologies GmbH in Healthy Volunteers. SEO and diligence focus: ShigETEC live, attenuated, oral vaccine, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: vaccine

Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma

The Phase I study investigates the use of autologous, activated T-cells enriched to target the GD2 antigen in patients with relapsed/refractory melanoma. Given the high unmet need in metastatic melanoma, where current therapies yield limited survival benefits, this approach could represent a novel immunotherapeutic strategy. The market for melanoma treatments is competitive, with established players focusing on checkpoint inhibitors and targeted therapies. However, the unique mechanism of action targeting GD2 may provide a differentiated offering. Diligence should focus on the safety profile and efficacy data from this trial, as well as potential regulatory pathways for accelerated approval based on unmet medical need.

Matched by modality_normalized: vaccine

A Phase 1, First-Time-in-Human (FTiH), Observer-blind, Randomized, Controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of Various Doses of an mRNA-based Respiratory Syncytial Virus (RSV) Investigational Vaccine in Healthy Participants 18-45 Years of Age

GlaxoSmithKline (GSK) is advancing an mRNA-based vaccine targeting Respiratory Syncytial Virus (RSV) in a Phase 1 clinical trial. The trial aims to evaluate the safety, reactogenicity, and immune response of various vaccine formulations in healthy adults aged 18-45. Given the significant unmet medical need for effective RSV vaccines, particularly in vulnerable populations such as infants and the elderly, successful outcomes could position GSK favorably in a competitive landscape that includes other mRNA vaccine developers. The trial's active status, despite not currently recruiting, indicates ongoing commitment to this asset, with potential implications for future partnerships or licensing opportunities. The market for RSV vaccines is expected to grow, driven by increasing awareness and demand for preventive measures against respiratory infections.

A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

GlaxoSmithKline's CV0501 mRNA COVID-19 vaccine is positioned as a booster option for individuals previously vaccinated with Comirnaty or Moderna vaccines. Given the ongoing need for booster vaccinations due to waning immunity and emerging variants, this asset could capture a significant share of the booster market. The competitive landscape includes established players like Pfizer-BioNTech and Moderna, as well as emerging mRNA candidates. Successful safety and immunogenicity results could enhance GSK's portfolio and strengthen its position in the rapidly evolving vaccine market.

Matched by modality_normalized: vaccine

A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey

The Phase IIb clinical trial for the CoronaVac® booster dose, sponsored by Sinovac Research and Development Co., Ltd., aims to evaluate the immunogenicity and safety of high and medium doses in healthy adults previously vaccinated with either CoronaVac® or Comirnaty. Given the ongoing global demand for COVID-19 vaccines and booster doses, this trial positions Sinovac to potentially enhance its market share in Turkey and other regions. The competitive landscape includes mRNA vaccines and other inactivated vaccines, necessitating a focus on demonstrating superior immunogenicity and safety profiles to maintain a competitive edge. The trial's suspension due to a change in plans may impact timelines and investor confidence, warranting close monitoring of future developments.

Matched by modality_normalized: vaccine

A Phase 2/3, Observer-Blind, Immuno-bridging, and Broadening Study of a Whole, Inactivated Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Vaccine (BBV152) in Healthy Adults

Ocugen's BBV152 is positioned to address the ongoing need for effective COVID-19 vaccines, particularly in populations previously vaccinated with mRNA or viral vector vaccines. The trial aims to demonstrate the immunogenicity of BBV152 in a demographically diverse U.S. population, potentially expanding its market reach. Given the competitive landscape, including established mRNA vaccines and emerging candidates, successful results could enhance Ocugen's market position and facilitate partnerships or licensing opportunities. The study's focus on bridging immunogenicity data from India to the U.S. may also attract interest from regulatory bodies and investors, emphasizing the importance of diverse population data in vaccine efficacy.

Matched by modality_normalized: vaccine

Phase II Study of Intratumoral Injection of rF-TRICOMTM in Patients With Metastatic Melanoma Who Have Detectable Tumor Associated T Cells

The Phase II study of rF-TRICOM in patients with metastatic melanoma aims to evaluate the safety and efficacy of intratumoral vaccine therapy. Given the increasing incidence of melanoma and the limited treatment options for advanced stages, this asset has potential commercial value in a competitive landscape dominated by immunotherapies such as checkpoint inhibitors. The trial's focus on patients with detectable tumor-associated T cells may position it favorably in the market, particularly if it demonstrates superior local and systemic responses compared to existing therapies. However, the termination of the study may raise concerns regarding the viability of this approach and necessitate further diligence on the reasons for discontinuation and the implications for future development.

Matched by modality_normalized: vaccine

Phase 2 Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (HPV2-2303)

The Phase 2 clinical trial (HPV2-2303) sponsored by Centre Oscar Lambret aims to evaluate the efficacy of secondary HPV vaccination in women over 45 years who are chronic HPV carriers and have undergone treatment for high-grade cervical lesions. Given the increasing incidence of HPV-related cancers and the potential for Gardasil 9 to enhance HPV clearance, this study addresses a significant unmet medical need in an aging population. The trial's dual-cohort design allows for a comparative analysis of vaccinated versus non-vaccinated patients, which could provide valuable insights into the vaccine's effectiveness and safety profile. If successful, the findings may bolster Gardasil 9's market position and expand its indications, potentially leading to increased adoption in clinical practice. The study is currently recruiting, with an estimated enrollment of 85 patients, and is expected to complete by the end of 2031, positioning it well within the timeline for potential market impact.

A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients

The trial aimed to compare the immunogenicity of two COVID-19 booster vaccines, BNT162b2 and JNJ-78436735, in solid organ transplant recipients, a population at high risk for severe COVID-19 outcomes. The termination of the trial due to recruitment difficulties may indicate challenges in engaging this specific patient population, which could affect the commercial viability of both vaccine candidates in this niche market. The results may provide insights into the efficacy of different booster strategies, potentially influencing future vaccination guidelines and market positioning for both sponsors.

Matched by modality_normalized: vaccine

Adherence to Guidelines for Influenza, Pneumococcal and Hepatitis B Vaccination in Adult Patients With Type 1 Diabetes Mellitus (AVADI-1).

The AVADI-1 study, sponsored by Jesús Moreno Fernández and conducted at Ciudad Real General University Hospital, evaluated adherence to vaccination guidelines for Influenza, Pneumococcal, and Hepatitis B in adult patients with Type 1 Diabetes Mellitus. With a cohort of 300 participants, the study highlights the importance of vaccination in this high-risk population, potentially influencing public health policies and vaccination strategies. The findings may provide insights for pharmaceutical companies involved in vaccine development and distribution, particularly in targeting diabetes patients. The study's completion and data availability could enhance market positioning for companies focusing on diabetes care and preventive measures.

Matched by modality_normalized: vaccine

Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses

The study investigates the immunogenicity of a third dose of mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) in kidney transplant recipients who exhibited inadequate antibody responses after two doses. Given the increasing recognition of vulnerable populations, such as transplant recipients, this research addresses a critical gap in COVID-19 vaccination strategies. The results could inform future vaccine recommendations and potentially expand market opportunities for mRNA vaccine manufacturers. The competitive landscape includes ongoing studies by other institutions focusing on similar populations, which may influence market positioning and pricing strategies. Diligence should consider the regulatory landscape and potential for expanded indications based on study outcomes.

Matched by modality_normalized: vaccine

Covid-19 Infection in Partially and Fully Vaccinated Cases: Cohort Study

This cohort study sponsored by Assiut University aims to assess the prevalence and severity of COVID-19 infections in individuals who have received at least one dose of a registered COVID-19 vaccine in Egypt. Given the ongoing global pandemic and the emergence of variants, understanding breakthrough infections is critical for vaccine manufacturers and public health authorities. The findings could influence vaccine development strategies, booster shot recommendations, and public health policies. The study's outcomes may also provide insights into the effectiveness of various vaccines in real-world settings, potentially impacting market positioning for vaccine developers. The competitive landscape includes major vaccine manufacturers such as Pfizer, Moderna, AstraZeneca, and Sinovac, all of whom are closely monitoring breakthrough infection rates to adapt their strategies.

Matched by modality_normalized: vaccine

A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women

Merck Sharp & Dohme LLC's GARDASIL (V501) is a quadrivalent HPV vaccine targeting HPV types 6, 11, 16, and 18, aimed at preventing cervical cancer and related diseases in young women aged 16 to 23. Given the increasing global focus on HPV vaccination and cervical cancer prevention, GARDASIL holds a significant position in the market. The completion of this Phase 3 trial reinforces its efficacy and safety profile, which may enhance its competitive edge against emerging HPV vaccines, particularly the 9-valent HPV vaccine. The trial's results may also support expanded market access and reimbursement strategies, particularly in regions with high cervical cancer incidence. Diligence should focus on market penetration strategies and potential regulatory hurdles in various jurisdictions.

A Post-marketing Clinical Study of a Third Dose of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Beijing): Immunogenicity, Safety and Antibody Persistence Assessments in Patients With Hypertension and/or Diabetes

The clinical trial, sponsored by China National Biotec Group Company Limited, aims to evaluate the immunogenicity, safety, and antibody persistence of a third booster dose of an inactivated SARS-CoV-2 vaccine in older patients with hypertension and/or diabetes. This demographic is particularly vulnerable to severe COVID-19 outcomes, thus presenting a significant market opportunity for booster vaccinations targeting this population. The trial's findings could enhance the vaccine's market positioning, especially in regions with high prevalence of these comorbidities. Competitive implications include the need for differentiation from other COVID-19 vaccines and boosters currently available, particularly those from Western pharmaceutical companies. Diligence considerations should focus on regulatory compliance, safety data, and the potential for expanded use in similar patient populations.